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The major histocompatibility complex class I protein HLA-C plays a crucial role as a molecule capable of sending
inhibitory signals to both natural killer (NK) cells and cytotoxic T lymphocytes (CTL) via binding to killer cell Ig-like
receptors (KIR). Recently HLA-C has been recognized as a key molecule in the immune control of HIV-1. Expression
of HLA-C is modulated by a microRNA binding site. HLA-C alleles that bear substitutions in the microRNA binding
site are more expressed at the cell surface and associated with the control of HIV-1 viral load, suggesting a role of
HLA-C in the presentation of antigenic peptides to CTLs. This review highlights the role of HLA-C in association with
HIV-1 viral load, but also addresses the contradiction of the association between high cell surface expression of an
inhibitory molecule and strong cell-mediated immunity. To explore additional mechanisms of control of HIV-1
replication by HLA-C, we address specific features of the molecule, like its tendency to be expressed as open
conformer upon cell activation, which endows it with a unique capacity to associate with other cell surface
molecules as well as with HIV-1 proteins.
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Introduction
The major histocompatibility complex (MHC) class I loci
are the most polymorphic mammalian genes. The human
MHC class I system includes 3 main loci, namely HLA-A,
-B and -C, and some non-classical HLA genes such as –E,
-F and –G. The HLA-B locus is the most polymorphic,
with 1795 proteins known, followed by HLA-A with 1290,
and HLA-C with 946 (http://www.ebi.ac.uk/imgt/hla/stats.
html). Among the classical MHC class I genes, HLA-C
has the least allelic variability [1].
MHC class I molecules consist of a 45 kDa heavy, α-chain
(divided in 3 subdomains, α1, α2 and α3) non-covalently
associated with a light β chain, the β2-microglobulin (β2m),
and a short (8-11mer) peptide antigen derived from the
degradation of intracellular proteins [2]. MHC class I
assembly occurs in the lumen of the endoplasmic reticulum
(ER) with the help of molecular chaperons like calreticulin,
ERp57 and tapasin [3]. After leaving the ER the trimeric
complexes egress through the Golgi complex to the plasma
membrane. At the plasma membrane they can interact with
two main types of ligands: the T cell receptor (TCR) of CD8
+ T cells and natural killer cells (NK) receptors including* Correspondence: alberto@gmail.com
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reproduction in any medium, provided the origimmunoglobulin receptors (KIRs), leukocyte immunoglobu-
lin receptors (LILRs) [4,5] and NKG2A/C [6].
It is generally agreed that HLA-C is surface-expressed at
levels much lower (sometimes said to be ten-fold lower)
than HLA-A and HLA-B [7] despite similar levels of tran-
scription and translation [8]. Several authors provided
evidence for transcriptional, post-transcriptional, as well as
post-translational impairments (reviewed in [9]). Due to
such considerable redundancy in the mechanisms account-
ing for low HLA-C expression, different HLA-C alleles may
be affected to various degrees in different cell types or
biological conditions. A post-translational biosynthetic
bottleneck appears nevertheless to be common, in that it
causes the backward accumulation of chaperone-associated
and deeply unfolded HLA-C heavy chain conformers of all
the 8 serologically defined (Cw*01 through Cw*08) alleles.
This bottleneck is due to the HLA-C-specific KYRV heavy
chain motif, initially noted by Zemmour and Parham [10]
and subsequently proposed to provide HLA-C with reduced
binding groove plasticity and selective peptide-assembly
properties [9].
The mature trimeric HLA-C complexes expressed at the
cell surface tend to dissociate and generate a pool of heavy
chains, lacking peptide and β2m. The surface expression of
free HLA-C heavy chains, also called “open conformers”,
is a hallmark of activated and transformed cells, including
lymphocytes [11,12]. The expression of HLA-C openentral Ltd. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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in human trophoblasts [13] and in other human cells
belonging to a variety of lineages [12].
An additional selective feature of HLA-C lies in its cyto-
plasmic domain containing a di-hydrophobic internalization
signal (DXSLI), which is specifically inhibited upon macro-
phage differentiation, allowing high HLA-C surface expres-
sion on macrophages [14]. The specific induction of
HLA-C expression on differentiated macrophages may
play a role in the down-modulation of the normal
CD8+ T cell response to specifically limit the lysis of
antigen-presenting cells (APC) that cross-present the
antigen [14]. Thus, it appears that complex mechan-
isms tightly regulate the expression of HLA-C, main-
taining significant intracellular levels and limiting
surface expression on resting cells, but also rapidly
mobilizing the intracellular pool to allow surface
expression after cell activation or differentiation.
HLA-C presents antigen to cytotoxic T lymphocytes less
efficiently than either HLA-A or -B [15]. In contrast,
HLA-C is an extremely good ligand for KIR receptors on
NK cells and protects target cells from lysis mediated by
NK cells [16]. The HLA-C-mediated protection is relevant
to many viral infections, including HCV [17,18] and HIV-1
[19-24]. Inhibitory HLA-C/KIR interactions influence the
outcome of HCV infection and confer protection [17]. Sev-
eral lines of evidence highlight the importance of NK cells
in the setting of HIV-1 infection [19-24]. Furthermore,
HIV-1 has developed a sophisticated pathway to modulate,
to its own advantage, the surface expression of MHC class
I molecules. The suppression of HLA-A and -B, but not
-C, results in escape of immune recognition of HLA-A and
–B peptides by CTL. At the same time an efficient NK in-
hibitory signal at the surface is maintained [25-31], point-
ing to a selective advantage for HIV-1, which results in
maintenance of a sufficient level of cell-surface HLA-C
expression.
Further complexity has been added by the discovery of
a post-transcriptional mechanism of HLA-C expression
control [32]. Specifically, such control depends on the
expression of an intact microRNA binding site in the 3′
UTR of the HLA-C gene. Strong genetic association be-
tween HLA-C alleles with a mutated microRNA binding
site, higher protein expression, and control of HIV-1 rep-
lication was reported. These findings are in contradiction
with the view of HLA-C as an inhibitory molecule and
call for a general reappraisal of the role of HLA-C in
HIV-1 infection.
MHC class I genes and control of HIV-1
Experimental evidence shows that CD8+ T cells play a
central role in controlling HIV-1 viremia during primary
infection as well as in the long-term suppression of viral
replication [33]. The correlation between expression ofspecific MHC class I alleles and HIV-1 control strongly
supports this idea. Early studies performed in the late
1980′s on small cohorts of AIDS patients reported an
increased frequency of C*04 and B*35 in HIV-1-infected
patients compared to non-infected controls [34], an ele-
vated C*04 frequency in patients with Kaposi’s sarcoma
and of C*07 in patients with opportunistic infections [35].
Subsequent studies reported an increased prevalence of
C*07 in HIV-1 positive individuals [36]. A larger study
published in 1999 established the association of C*04 and
B*35 with rapid development of AIDS-defining conditions
in Caucasians [37], and also showed that maximum homo-
zygosity at the HLA-B locus was more detrimental than
homozygosity at either HLA-A or -C. A follow up study
from the same group showed that peptide presentation
properties of particular B*35 subtypes explain much of this
association [38]. The dominance of HLA-B in the control
of HIV-1 infection is supported by several studies which
associated HLA-B*57, B*5801 and B*27 with slower dis-
ease progression rates (time to AIDS) and strong virologic
(viral load) and immunologic control (CD4 count) [39-
48], while B*35, B*5802 and B*18 were associated with in-
effective control of viral replication and rapid progression
to AIDS [37,43,44,47,49,50]. In addition, a significantly
greater number of CD8+ T cell responses are HLA-B
restricted, compared to HLA-A and -C. Variation in viral
set-point, absolute CD4 count, and rate of disease progres-
sion are strongly associated with particular HLA-B, but
not –A or –C alleles [43]. Recently, a study on blood
donors in China who were contaminated by a narrow
source blood-born virus showed that HLA-B exerts a
greater selection pressure on HIV evolution than other
HLA molecules [51].
On the other hand, there is evidence of interdependent
protective effects of the HLA-C*0401-B*8101, HLA-
C*1203-B*3910 and HLA-A*7401-B*5703 haplotypes that
cannot be explained solely by linkage to a protective HLA-
B allele. Therefore, although individual HLA alleles, particu-
larly HLA-B, can have a strong impact, HIV-1 control is
likely to be influenced by the additive effect of some or all
the other HLA alleles present [45]. Other HLA alleles com-
binations like HLA-B*5701-C*0602, HLA-B*2705-C*0102,
or HLA-B*3801-C*1203 also exert a strong effect on non-
progression, reinforcing the hypothesis of an additive effect
of protective HLA alleles [48,52]. More recently, a study on
HIV-infected children identified HLA-C*02 as a protective
allele while confirming a strong protective effect of the B*27
allele [53].
HLA-C drives viral evolution through the selection of
CTL escape mutants. A recent study used three phylo-
genetic correction methods across a full HIV-1 subtype
C proteome and identified amino acids conferring either
susceptibility or resistance to CTLs [54]. Three hundred
and ten groups of HLA-amino acid associations were
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HLA combinations (immunological set). The immuno-
logical set with the most individual associations was
found within Nef and included a B*44-restricted epitope
(molecules of the Bw4 subfamily of HLA-B alleles). The
next largest immunological sets were in Nef, Tat and Pol
and included six associations involving a C*0404-
restricted epitope as well as two B*42-restricted epitopes
[55]. CTL escape mutants were also identified in a
Cw*12 restricted pol epitope [54].
Recently, genome-wide association studies (GWAS) were
applied to the study of genetic control of HIV-1. These
studies do not rely on candidate gene selection and have
the potential to identify new genomic regions and pathways
affecting human diseases [56]. The first study identified gen-
etic polymorphisms associated with viral load during the
asymptomatic phase of infection, as well as time to HIV-1
disease progression [57]. Two independently acting groups
of polymorphisms associated with HLA loci B and C were
identified explaining 9.6% and 6.5%, respectively, of the total
variation in viral set point. The first polymorphism, located
in the HLA complex P5 (HCP5), is in high linkage disequi-
librium with the B*5701 allele [58]. The second polymorph-
ism (C/T) is located in the 5′ region of the HLA-C gene
35 kb away from transcription initiation. This single nucleo-
tide polymorphism (SNP) associates with differences in
HLA-C expression levels. The protective allele (C SNP)
leads to lower viral load and is associated with higher
expression of HLA-C [57].
A second GWAS (The International HIV Controllers
Study) [59] conducted in a multiethnic cohort of HIV-1
controllers and progressors analyzed the effects of individ-
ual amino acids within the classical HLA proteins. In the
group of individuals of European ancestry, 4 independent
markers of association were identified, which included the
−35 kb and the HCP5 SNPs previously identified [57]. In
addition, B*57.01, B*27:05, B*14/C*08:02, B*52, and A*25
were identified as protective alleles and B*35 and C*07 as
risk alleles. The study also evaluated the impact of specific
amino acid positions within the HLA molecules and identi-
fied six residues as independent markers associated with
control of HIV-1: Arg97, Cys67, Gly62, and Glu63, all in
HLA-B; Ser77 in HLA-A and Met304 in HLA-C. Collectively
these residues explained 20% of the variance. Interestingly,
all these residues, with the exception of Met304 of HLA-C,
are in the peptide-binding groove. Position 304 is a biallelic
variant (Val/Met) located in the transmembrane domain of
HLA-C, which is in moderate linkage disequilibrium with
the −35 SNP associated with HLA-C expression level.
Therefore mechanisms other than peptide selection by
polymorphic HLA-C residues may underlie the association
between HLA-C expression and HIV-1 control [59]. Col-
lectively, the data generated by the GWAS confirmed the
dominance of HLA-B in host control of HIV-1, but alsorevealed a novel mechanism of control related to HLA-C
expression.
The association between the −35 SNP and HIV-1 viral
load has been questioned in a work by Corrah and collea-
gues who showed that differences in HLA-C expression
across −35 SNP genotypes can be attributed primarily to
the very low expression of a single allelic product, HLA-
Cw*07 [60].
Some individuals with the reported protective -35CC
SNP genotype exhibit high viral loads. HIV-1 variants iso-
lated in these patients counteract HLA-C-mediated im-
mune control of HIV-1 by enhancing Nef mediated viral
infectivity. This was not due to an acquired ability of Nef to
down-modulate HLA-C or in a more efficient ability to
down-modulate HLA-A and –B, but rather to an indirect
mechanism interfering with T-cells function and MHC-II
antigen presentation [61].
Post-transcriptional regulation of HLA-C expression
Recently, Kulkarni et al. [32] discovered that the −35 kb
SNP is not the causal variant for differential HLA-C ex-
pression, but rather marks another polymorphism in the
3′ UTR region of HLA-C that directly controls the levels
of HLA-C [32]. The 3′ UTR variant affects binding of a
microRNA (miR-148a) to its target site resulting in rela-
tively low surface expression of HLA-C alleles that bind
this miRNA (“inhibited alleles”) and high expression of
HLA-C alleles that escape the miRNA control (“escape
alleles”). HLA-C alleles, such as C*01, C*03, C*04, C07*,
C*14 and C*17, contain an intact miR-148 binding site,
and their expression is down-regulated (“inhibited
alleles”). On the contrary, C*02, C*05, C*06, C*08, C*12,
C*15 and C*16, containing a disrupted binding site, are
highly expressed (escape alleles). These findings offer a
rational explanation of different HLA-C expression levels
initially reported to be associated with the −35 kb SNP
and are also consistent with previous genetic association
studies which identified C*04 and C*07 (inhibited alleles)
as risk alleles [34-36] and C*02 and C*12 [52] (escape
alleles) as protective alleles [53]. A subsequent study
showed that the common ancestor of all extant HLA-
C alleles was suppressed by miR-148a and that substi-
tutions that prevent miR-148a binding arose by a re-
combination event between an ancestral HLA-C allele
and an HLA-B allele of the HLA-B*07-like lineage.
This resulted in conversion of the 3′ UTR of the ori-
ginal HLA-C allele by the paralogous HLA-B region.
This event is likely to have occurred 3 to 5 million
years ago, after the split of humans from great apes,
resulting in HLA-C variants that escape control by
miR-148 [62]. The frequency of the escape alleles in
worldwide populations is high, constituting an esti-
mated 32.8% of HLA-C alleles. In addition, many
polymorphisms and functional motifs specific for HLA-
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indicating that selection has been instrumental in the di-
versification of the escape lineage [62].
On the other hand, the inhibited alleles may also provide
benefit, since they have been maintained in evolution, and
they have been identified as restricting elements for HIV-
specific CTL clones [63-68]. Notably, with the exception
of one CTL clone restricted to HLA-C*15 (an escape
allele) [63], all other clones are restricted to inhibited
HLA-C alleles like HLA-C*01 [69], -C*03 [63,66], -C*04
[64,65,67,68] and -C*07 [63]. Furthermore, Cw*07
restricted CTLs were detected in non-progressor patients
[70], and a Cw*04 restricted epitope was associated with
the generation of CTLs escape mutants [55].
HLA-C and NK cells
NK cells express receptors (KIR) which interact with the α1
domain of MHC class I molecules resulting in inhibition or
activation of cytolysis [71]. HLA-C alleles are the main in-
hibitory ligands for KIRs, protecting target cells from lysis
mediated by NK cells [16,72]. HLA-C/KIR interactions have
been shown to play a key role in placentation [73].
KIR distinguishes HLA-C alleles into two groups, namely
C1 and C2, depending on a dimorphism present in the α1
domain [74,75]. In particular, KIR2DL2 and 3 bind with
greater affinity to HLA-C group 1, while KIR2DL1 bind to
HLA-C group 2 [76]. Homozygosity for HLA-C1 alleles
and KIR2DL3 is associated with resolution of HCV infec-
tion as compared to homozygosity or heterozygosity for
HLA-C2 [17]. In the case of HIV-1, resistance to infection
has been associated with the presence of inhibitory KIR in
the absence of their HLA-C ligands [20] The activating
receptor KIR2DS4 was associated with high viral load and
accelerated transmission although this effect was independ-
ent of the putative ligand HLA-Cw*04 [22]. HLA-C1 alleles
were also associated with an increased magnitude of NK
cell response in HIV-1 infected subjects [24]. The
KIR2DL2-HLA-C1 compound was also shown to drive
viral evolution in vivo since KIR2DL2-associated HIV-1
sequence polymorphisms were shown to enhance the
binding of inhibitory KIRs to HIV-1 infected CD4+ T cells
and to reduce anti-viral activity of KIR-positive NK cells
thereby enabling HIV-1 to escape the potential protective
role of KIR [77].
Another KIR/HLA compound genotype relevant to HIV-
1 control is KIR3DL1 and KIR3DS1, which encode recep-
tors for molecules of the Bw4 subfamily of HLA-B alleles.
The activating allele, KIR3DS1, when present in combin-
ation with Bw4, is associated with lower viral load, slower
decline of CD4+ T cells and delayed progression to AIDS
[21]. KIR3DS1 is also associated with strong inhibition of
viral replication [19]. The importance of the KIR3DL1/
KIR3DS1 locus in control of viral set point was recently
confirmed by a GWAS that assessed the copy numbervariant of KIR3DL1/KIR3DS1. The study showed that an
increase in KIR3DS1 count associates with a lower viral set
point if its putative ligand is present, as does an increase in
KIR3DL1 count in the presence of KIR3DS1 and the appro-
priate ligands for both receptors, suggesting that the relative
amounts of activator and inhibitory KIR regulate the expan-
sion of antiviral NK cells [23].
It should be considered, however, that inhibition by HLA-
B allotypes is less common compared to inhibition by
HLA-C since it has only been shown for the Bw4 subfamily.
In contrast, since nearly all KIR allotypes worldwide contain
KIR2DL1 along with either KIR2DL3 or KIR2DL2, HLA-C
molecules almost always inhibit a subset of each individual’s
NK cell population.
Although generally considered NK cell receptors, KIR are
also expressed by a large fraction of effector memory Tcells,
which, like NK cells, are immediate effector cells that are
cytotoxic and produce IFN-γ (reviewed in van Bergen and
Koning [78]). On cytotoxic T cells, KIRs modulate signals
driven by the T-cell receptor and inhibit cytokine secretion,
degranulation, and proliferation. In HIV-1 infection, KIR
expression on cytotoxic T cells is progressively upregulated,
and this correlates with the level of viral replication [79].
Interestingly, the upregulation of KIR occurs in individuals
who do or do not express the respective KIR ligands, sug-
gesting a possible ligand-independent blockade of TCR acti-
vation [79].
Virion HLA-C molecules and HIV-1 infectivity
During the process of budding from the cell membrane,
MHC class I and II molecules are incorporated into the
HIV-1 envelope together with other cell proteins [80-85].
HIV-1 viral particles have been shown to carry more MHC
molecules than Env trimers [86-88]. The process of host cell
protein incorporation is neither random nor dependent on
the amount of protein on the cell membrane, since some
highly expressed proteins such as CD4, CD45, CCR3, CCR5
or CXCR4, are not incorporated. The preferential incorpor-
ation in the budding envelopes suggests a role in the patho-
genesis of HIV-1 [80]. For instance, virion-associated MHC
class II molecules have been shown to confer higher viral
infectivity, possibly enhancing CD4 binding [89,90].
There is evidence that virion HLA-C molecules play a
role in HIV-1 infectivity. Fusion between the viral enve-
lope and the cell membrane is increased by HLA-C [91].
This effect is not due to binding to a specific cellular lig-
and, since the natural CD8 MHC class I ligand is not
expressed on cells susceptible to HIV-1 infection. Cosma
et al. reported that MHC class I negative cells are non-
permissive for replication of primary HIV-1 isolates, and
transfection of HLA-C restores their permissivity. This
effect of HLA-C is also evident, but to a lesser extent,
with T cells line-adapted viruses [92]. HLA-C molecules
associate non-covalently with the HIV-1 envelope
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positive virions displays conformational changes, which
include an enhanced exposition of epitopes normally
available upon CD4 binding. In addition, virus incorpor-
ation of HLA-C reduces the susceptibility to neutralizing
antibodies [92].
The effect of HLA-C on HIV-1 infectivity was further
studied by Matucci et al. [93] who showed that fusion effi-
ciency is reduced in HLA-C silenced cells and that
pseudoviruses produced in HLA-C silenced cells are sig-
nificantly less infectious compared to those produced in
non-silenced cells. The study also confirmed the associ-
ation between HLA-C and gp120 demonstrating that
HLA-C molecules are detectable, together with gp120,
CD4 and CCR5 within molecular complexes which form
on cells during the process of HIV-induced cell-to-cell
fusion (fusion complexes).
These studies addressed the association between gp120
and HLA-C using an HLA-C specific monoclonal antibody,
L31 [11], which was originally derived from a mouse immu-
nized with purified HIV-1 virions [94] and later shown to
bind all HLA-C and a few rare HLA-B open conformers
[94,95]. L31 binding to HLA-C is strictly dependent on the
presence of aromatic amino acids (Phe or Tyr, present in
HLA-C and certain HLA-B alleles) at position 67 of
the locus-specific motif on the α1 helix [11], which is
buried deep in the binding groove [96]. The gp120/
HLA-C association appears, therefore, to selectively
involve the open conformers of HLA-C. Enhancement
of HIV-1 infectivity was observed in cell lines trans-
fected with three inhibited HLA-C alleles (C*03, *04
and *07) and one escape allele (C*12) expressed in
heterozygosity with C*07 (see Table 1).Table 1 principal characteristics of the main HLA-C variants
HLA-C allele miR418a site/expression
[32,34-36,52,53,59]
−35 kb
SNP [32]
Val/Met
304 [57,59]
KIR gro
type [7
01.02 Intact/Low C Val* C1
02.02 Deleted/High C Val* C2
03.03, .04 Intact/Low T Val* C1
04.01 Intact/Low T Val* C2
05.01 Deleted/High C Met*/Val* C2
06.02 Deleted/High C Met*/Val* C2
07.01, .02, .04 Intact/Low T Val C1
08.01, .02, .04 Deleted/High C Met*/Val* C1
12.02, .03 Deleted/High C Met*/Val* C1*
14.02 Intact/Low C Val* C1*
15.02, .05, .06 Deleted/High T Met*/Val* C2*
16.01, .02, .04 Deleted/High T Val* C1*
17.01 Intact/Low T Val* C2*
*: data obtained by sequence alignment analysis.
**: C*12/C*07.
NT not tested.In T lymphocytes, HIV-1 assembly, budding, and release
occur at the plasma membrane, while in macrophages they
occur in intracellular compartments such as the late endo-
somes [97]. This process is coordinated by the viral protein
Gag [98]. MHC class II molecules, which are expressed on
macrophages and activated T cells, relocate Gag to late
endosomes and substantially decrease viral production and
release from the cell surface [97]. HLA-C molecules, like
other MHC class I molecules, are mobilized from late endo-
somes to the cell surface [99] and may therefore play a simi-
lar role, acting as chaperones of the viral envelope proteins
and participating to the process of virus assembly and
budding.
MHC class I open conformers have been shown to be
able to cis-associate both with themselves and with a var-
iety of membrane receptors, including CD3, CD8αβ,
CD25, Ly49A and IL-15Rα [100] and tend to maintain
an ordered and non-denatured structure. HLA-C binds
weakly to β2m and has the longest reported half-life
compared to other free MHC class I heavy chains [101].
This property may confer to HLA-C open conformers a
selective propensity for associating with viral proteins.
Conclusions
HLA-C can influence the outcome of HIV-1 infec-
tion in at least three distinct and potentially opposite
ways: (a) promoting effective CTL recognition and
lysis of HIV-infected cells, (b) inhibiting NK cell rec-
ognition and lysis of infected cells, and (c) favoring
the formation of infective virions via its association
with the envelope protein. The extent to which gen-
etic polymorphisms associated with control of HLA-
C expression levels influence these three propertiesup
4,75]
CTL
restriction
Association
with control
Association with
progression
Increase of HIV-1
infectivity [92,93]
[69] NT
[53] NT
[63,66] Yes
[63-68] [34,37] Yes
NT
NT
[63,70] [36] Yes
NT
[54] [54] Yes ?**
NT
[63] NT
NT
NT
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genetic association between high expression of HLA-
C and control of HIV-1 suggests that, at least, in the
initial setting of HIV-1 infection, the role of HLA-C
in inducing an effective CTL response dominates
over other functions of the molecule. However, the
role of the escape (highly expressed) HLA-C allo-
types in the induction of CTL responses needs fur-
ther investigation, since only a handful of HLA-C
specific CTL clones restricted to escape alleles have
been reported so far, while the majority of clones are
restricted to inhibited alleles [102] (see Table 1). In
addition, no significant associations between HIV-1
control and amino acid positions located in the
HLA-C peptide binding pocket were identified by the
GWAS, as it would be predicted if selection of anti-
genic peptides by HLA-C were to play a major role
in control [59], by analogy with HLA-B. Thus, if
high cell surface expression of HLA-C suggests a
more potent induction of cytotoxic T cell responses,
other properties and functions of the escape alleles
may contribute to the control of viral replication.
The main feature of HLA-C molecules is their poor
assembly efficiency, which results in intracellular ac-
cumulation as open conformers. Differences in bind-
ing affinity to their cognate ligand, β2m, or to
alternative ligands may confer to each allelic variant
of HLA-C a selective capacity to function as
accessory molecule in the process of virus assembly
and budding. In addition, preferential association
with alternative ligands may affect the pattern of cell
surface expression of the alternative isoforms. Ac-
cordingly, escape alleles may have a higher affinity
with β2m, resulting in higher surface expression of
trimeric complexes, but also lower propensity to as-
sociate with viral proteins. This property would con-
fer to lymphoid cells of individuals bearing HLA-C
escape allotypes a higher sensitivity to CTLs, but
also an intrinsically lower capacity to support viral
replication. Studies addressing the characterization of
the HLA-C molecular isoforms on infected cells
expressing escape versus deleted alleles are warranted
to gain novel insights into the potential protective or
pathogenic properties of HLA-C in HIV-1 infection.
Such studies might help clarifying the apparent
contradiction of the association of higher surface ex-
pression of an inhibitory molecule with control of
HIV-1 and open new perspectives on the role of
HLA-C in the modulation of host-virus interactions.
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